Inotek Pharmaceuticals Announces Conversion of $21 Million Principal Amount of 5.0% Convertible Senior Notes due 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that $20,970,000 of its 5.0% Convertible Senior Notes due 2020 (the “2020 Notes”) maturing February 15, 2020 have been converted into shares of common stock of the Company. The 2020 Notes converted into approximately 3.86 million shares, includ